2 Minutes with Joey - ABT Stock News cover art

2 Minutes with Joey - ABT Stock News

2 Minutes with Joey - ABT Stock News

By: 2 Minutes with Joey
Listen for free

LIMITED TIME OFFER

£0.99/mo for the first 3 months. Terms apply.
Two minutes with Joey on Abbott Laboratories (ABT) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey Social Sciences
Episodes
  • ABT Today - Jul 24: Medtech Stocks Rebound

    ABT Today - Jul 24: Medtech Stocks Rebound
    Jul 24 2026
    Hey there! It's Joey, your friendly neighborhood investor, and I’m here to break down what happened with Abbott Laboratories today. So, ABT had a pretty solid day, up about 2.7%. Not too shabby, right?

    So, what went down? The stock got a nice bump, which is a refreshing change in the medtech space. It seems like after a rough patch for a lot of medtech stocks, Abbott’s finally catching a break. People are starting to see it as a bargain. Yeah, that one stung for those who sold off.

    Now, why the boost? Well, a few articles are buzzing about how Abbott’s earnings brought in some fresh attention. Investors are realizing that it might still be undervalued compared to peers like Boston Scientific and ResMed, which, let’s be real, aren’t exactly killing it either. There’s also chatter about Abbott possibly being a solid option for retirement income given its dividend profile. So, a mix of hopeful vibes and some stock comparisons got folks interested again.

    One quick thing on the horizon? There’s ongoing talk about Abbott’s potential to keep growing, especially as the medtech market starts to shift. It’s definitely something to keep in mind as the industry evolves.

    Wrapping it up, it’s nice to see Abbott making some moves today. Just remember, this is all for fun and info, not financial advice. Catch you later!
    Show More Show Less
    1 min
  • ABT Today - Jul 23: Earnings Draw Attention

    ABT Today - Jul 23: Earnings Draw Attention
    Jul 23 2026
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today I’m breaking down Abbott Laboratories, or ABT for short. So, was it a green or red day? It was a green day, barely, up just a smidge at about 1%!

    Now, let’s get into what went down. Folks were buzzing about Abbott's earnings report. Revenue popped up, but earnings took a bit of a hit. You know how that goes—good news and bad news, all rolled into one. It seems like investors were trying to wrap their heads around that mixed bag. So, they pushed the stock up a little, but it wasn't a huge surge.

    As for the why, there’s a lot of chatter about how Abbott’s earnings are still under the radar compared to what people think it should be worth. Some articles mentioned that it’s still below fair value, which is a classic investor dilemma. Plus, there’s this whole thing about how Abbott is facing some stiff competition from other healthcare giants like Boston Scientific and ResMed. They’re kind of showing off what they’ve got that Abbott doesn’t, which can really shake things up in the market. And let’s not forget the comparisons to Johnson & Johnson—those two are on totally different paths right now.

    Looking ahead, one thing to keep in mind is that Abbott’s got a profit test coming up. That’s gonna be a big deal, since it’ll show if they can really bounce back and tackle the challenges they’re facing.

    So, to wrap it up, ABT had a slight bump today thanks to some buzz around its earnings, even though it’s still got some hurdles to jump over with competition and profit expectations. Just remember, I’m here to keep you informed and entertained, not to give any financial advice. Catch you later!
    Show More Show Less
    2 mins
  • ABT Today - Jul 22: Legal Overhang Fades

    ABT Today - Jul 22: Legal Overhang Fades
    Jul 22 2026
    Hey there! It’s Joey, your friendly investor buddy, here to break down the day for you. Today, we’re talking about Abbott Laboratories, and it was a pretty chill day, just a slight bump up, closing up a smidge at 0.23%.

    So, what went down? Well, Abbott’s stock kinda just hovered around, barely moving much. But here’s the scoop: it seems like folks are starting to think that Abbott might be undervalued, like, by a lot—up to 32%! That’s got some people’s attention. Meanwhile, it was noted that Abbott’s been underperforming compared to other companies in the same space, which isn’t great, but hey, at least they’re steady with their medical devices and diagnostics.

    Now, why is all this happening? A couple of articles pointed out that there’s some legal baggage that’s starting to fade away, which is giving investors a little bit of hope. Plus, there’s chatter about how Abbott’s medical devices are crucial for their growth, and people are watching closely to see how they handle some upcoming challenges. So, it’s a mixed bag of feelings out there, but that legal stuff being less of a worry is a good sign overall.

    Oh, and just so you know, there’s a major test coming up for Abbott’s medical device sector. That could really shake things up, one way or another.

    Alright, that’s the scoop for today! Just remember, this info is for entertainment and to keep you in the loop, not financial advice. Catch you later!
    Show More Show Less
    1 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet